ArticleGenes & cancer2011
Cancer Epigenetics for the 21st Century: What's Next?
Article in Genes & cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review.Drug design, development and therapy · 2015Pooled it
- Epigenetics and Herbs: Potential Therapeutic Strategies for Osteoarthritis of the Knee.Journal of pain research · 2025Review
- Universal penalized regression (Elastic-net) model with differentially methylated promoters for oral cancer prediction.European journal of medical research · 2024Article
- Role of endothelial cells in vascular calcification.Frontiers in cardiovascular medicine · 2022Review
- Mammalian Sirtuins and Their Relevance in Vascular Calcification.Frontiers in pharmacology · 2022Review
- Clinical impact of PTEN methylation status as a prognostic marker for breast cancer.Journal, genetic engineering & biotechnology · 2021Article
- Circulating and Tissue Expression Profile of MicroRNAs in Primary Hyperparathyroidism Caused by Sporadic Parathyroid Adenomas.JBMR plus · 2021Article
- LncRNA NUTM2A-AS1 positively modulates TET1 and HIF-1A to enhance gastric cancer tumorigenesis and drug resistance by sponging miR-376a.Cancer medicine · 2020Article
- Epigenetics in Inflammatory Breast Cancer: Biological Features and Therapeutic Perspectives.Cells · 2020Review
- Roles of Histone Acetylation Modifiers and Other Epigenetic Regulators in Vascular Calcification.International journal of molecular sciences · 2020Review
- Gender Predilection in Sporadic Parathyroid Adenomas.International journal of molecular sciences · 2020Review
- Differences in DNA Methylation Between Disease-Resistant and Disease-Susceptible Chinese Tongue Sole (Frontiers in genetics · 2019Article
- Ten-eleven translocation 1 dysfunction reduces 5-hydroxymethylcytosine expression levels in gastric cancer cells.Oncology letters · 2018Article
- Identification of a novel leukemic-specific splice variant of DNMT3B and its stability.Medical oncology (Northwood, London, England) · 2017Article
- Epigenetic modifications of interleukin-6 in synovial fibroblasts from osteoarthritis patients.Scientific reports · 2017Article
- Genome-wide DNA methylation profile identified a unique set of differentially methylated immune genes in oral squamous cell carcinoma patients in India.Clinical epigenetics · 2017Article
- Article
- DNMT3B isoforms without catalytic activity stimulate gene body methylation as accessory proteins in somatic cells.Nature communications · 2016Article
- Epigenetics in non-small cell lung cancer: from basics to therapeutics.Translational lung cancer research · 2016Review
- The association of PTEN hypermethylation and breast cancer: a meta-analysis.OncoTargets and therapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery of global DNA hypomethylation events in human tumors in the early 1980s and the identification of CpG island promoter hypermethylation of tumor suppressor genes in cancer cells in the mid 1990s opened the door to the current excitement about the contribution of epigenetic disruption to human disease. The recent gigantic advances in technology make it possible to obtain complete DNA methylomes, histonomes, and non-coding RNA transcriptomes for many biological settings and their associated disorders. Furthermore, whole genome sequencing analyses yields an increasing number of mutated epigenetic genes in neoplasia. It is time to sit back, enjoy the show with a little help of friendly bioinformatic tools, and wonder about what will happen next.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.